This randomized, placebo controlled, double blind study comparing safety and efficacy of Ambroxol with current standard of care versus Placebo and standard of care in hospitalized patients with moderate COVID-19 will be conducted for a duration of 6 months at the Department of Clinical Pharmacology in collaboration with Department of Medicine, Seth GSMC and KEMH, Mumbai only after Ethics Committee approval. Patients who are diagnosed to have COVID -19 per RT PCR and admitted with moderate COVID-19. Based on eligibility criteria, they will be screened, counselled and enrolled in the study. A total of 60 patients (30 in Ambroxol group and 30 in Placebo group) will be recruited. They will be randomized by Sequentially Numbered Opaque Sealed Envelope (SNOSE) technique with an allocation of 1:1 maintained for both groups. A pre-designed case record from will be used to capture all the relevant parameters during the study. Chest X ray will be performed at the baseline and again before the discharge. In Group A: 30 patients will be given Tablet Ambroxol 60 mg orally TDS till discharge or for 14 days whichever is earlier along with SOC. In Group B: 30 patients will be given matching placebo tablets + SOC till discharge or for 14 days whichever is earlier. They will be evaluated for proportion of patients showing clinical improvement, time to clinical improvement and overall survival of patients. A Clinical Improvement Scale [ordinal 8-point scale ( Ranging from ambulatory to death and acknowledges the severity of illness over time] will be administered at baseline, day 1, day 3, day 5, day 7 and day 10 or at discharge, whichever is earlier. In case the patient is admitted beyond day 10, the scale will be administered till day 10 as per the above-mentioned schedule and again at discharge.